Purdue Pharma announced that the FDA has approved a new 15mcg/hr dosage strength for Butrans (buprenorphine) Transdermal System.

Butrans is a Schedule III opioid analgesic indicated for moderate to severe chronic pain when continuous opioid analgesia is needed for an extended time period. 

RELATED: Pain Management Resource Center

Specifically, buprenorphine is a partial agonist at mu opioid receptors, an antagonist at kappa opioid receptors, an agonist at delta opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors. Its clinical actions result from binding to the opioid receptors.

Butrans is already available in 5mcg/hr, 10mcg/hr, and 20mcg/hr strength transdermal patches. Purdue Pharma  expects to launch Butrans 15 mcg/hr in October 2013.

For more information call (888) 726-7535 or visit Butrans.com.